Clinical trial
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage…
NCT00408408 · NSABP Foundation Inc, Other · Unknown status
Key facts
| NCT number | NCT00408408 |
|---|---|
| Title | Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery |
| Official title | A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science… |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, capecitabine, cyclophosphamide, docetaxel, doxorubicin hydrochloride (Adriamycin), gemcitabine hydrochloride |
| Enrollment | 1,206 |
| Start date | Nov 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2018 |
| First posted | Dec 7, 2006 |
| Last update posted | Sep 18, 2017 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: